References
- HeijlALeskeMCBengtssonBReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol20021201268127912365904
- BeanGWCamrasCBCommercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differencesSurv Ophthalmol200853Suppl 1S69S8419038626
- NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther200118520521511783457
- YeeRWNorcomEGZhaoXCComparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture systemAdv Ther200623451151917050493
- KahookMYNoeckerRJComparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tearsCornea200827333934318362664
- KahookMYNoeckerRQuantitative analysis of conjunctival goblet cells after chronic application of topical dropsAdv Ther200825874375118670744
- BaudouinCRianchoLWarnetJMBrignoleFIn vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprostInvest Ophthalmol Vis Sci20074894123412817724196
- HorsleyMBKahookMYEffects of prostaglandin analog therapy on the ocular surface of glaucoma patientsClin Ophthalmol2009329129519668581
- UusitaloHPillunatLERopoAEfficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24 month results of a randomized, double-masked Phase III studyActa Ophthalmol201088121920420586
- UusitaloHChenEPfeifferNSwitching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medicationActa Ophthalmol20108832933620546237
- GandolfiSParedesTGoldbergIComparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucomaEur J Ophthalmol Epub June 24, 2011